Targeting p53 by small molecules in hematological malignancies

Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents

(2012) Merav Leiba et al.   BRITISH JOURNAL OF HAEMATOLOGY

Cell Death via DR5, but not DR4, Is Regulated by p53 in Myeloma Cells

(2012) S. Surget et al.   CANCER RESEARCH

Targeting the p53 signaling pathway in cancer therapy – the promises, challenges and perils

(2012) Alexander H Stegh   EXPERT OPINION ON THERAPEUTIC TARGETS

The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status

(2012) G. Zauli et al.   HAEMATOLOGICA

Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer

(2012) Sören Lehmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapeutic advancement of chronic lymphocytic leukemia

(2012) Kang Lu et al.   Journal of Hematology & Oncology

HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas

(2012) Angela M Sosin et al.   Journal of Hematology & Oncology

Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase Is Mediated by Point Mutations of p53, but Can Be Overcome with the p53 Targeting Agent RITA

(2012) R. J. Jones et al.   MOLECULAR CANCER THERAPEUTICS

Targeting p53 via JNK Pathway: A Novel Role of RITA for Apoptotic Signaling in Multiple Myeloma

(2012) Manujendra N. Saha et al.   PLoS One

HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma

(2011) R. J. Jones et al.   BLOOD

Translational approaches targeting the p53 pathway for anti-cancer therapy

(2011) Frank Essmann et al.   BRITISH JOURNAL OF PHARMACOLOGY

Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737

(2011) Kensuke Kojima et al.   CANCER

NPMc+ AML cell line shows differential protein expression and lower sensitivity to DNA-damaging and p53-inducing anticancer compounds

(2011) Qiao Jing Lew et al.   CELL CYCLE

RITA enhances chemosensivity of pre-B ALL cells to doxorubicin by inducing p53-dependent apoptosis

(2011) Ahmad Kazemi et al.   Hematology

p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells

(2011) L F Peterson et al.   LEUKEMIA

Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia

(2011) E McCormack et al.   LEUKEMIA

Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21)

(2011) E Drakos et al.   LEUKEMIA

A comprehensive study of TP53 mutations in chronic lymphocytic leukemia: Analysis of 1287 diagnostic and 1148 follow-up CLL samples

(2011) Sona Pekova et al.   LEUKEMIA RESEARCH

Frequent and Simultaneous Epigenetic Inactivation of TP53 Pathway Genes in Acute Lymphoblastic Leukemia

(2011) Amaia Vilas–Zornoza et al.   PLoS One

Enhancement of imatinib-induced apoptosis of BCR/ABL-expressing cells by nutlin-3 through synergistic activation of the mitochondrial apoptotic pathway

(2010) Tetsuya Kurosu et al.   APOPTOSIS

A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma

(2010) G. Gorgun et al.   BLOOD

Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia

(2010) J. Long et al.   BLOOD

Nutlin's two roads toward apoptosis

(2010) Qi Zhang et al.   CANCER BIOLOGY & THERAPY

Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma

(2010) Manujendra N. Saha et al.   CANCER BIOLOGY & THERAPY

MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity

(2010) Manujendra N. Saha et al.   CANCER BIOLOGY & THERAPY

MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma

(2010) Linhua Jin et al.   CANCER LETTERS

Blockade of Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase and Murine Double Minute Synergistically Induces Apoptosis in Acute Myeloid Leukemia via BH3-Only Proteins Puma and Bim

(2010) W. Zhang et al.   CANCER RESEARCH

Dasatinib Plus Nutlin-3 Shows Synergistic Antileukemic Activity in Both p53wild-type and p53mutated B Chronic Lymphocytic Leukemias by Inhibiting the Akt Pathway

(2010) G. Zauli et al.   CLINICAL CANCER RESEARCH

APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells

(2010) Dina Ali et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

RITA Inhibits Multiple Myeloma Cell Growth through Induction of p53-Mediated Caspase-Dependent Apoptosis and Synergistically Enhances Nutlin-Induced Cytotoxic Responses

(2010) M. N. Saha et al.   MOLECULAR CANCER THERAPEUTICS

1,25-Dihydroxyvitamin D3 Enhances the Apoptotic Activity of MDM2 Antagonist Nutlin-3a in Acute Myeloid Leukemia Cells Expressing Wild-type p53

(2010) T. Thompson et al.   MOLECULAR CANCER THERAPEUTICS

The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53- and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid Leukemias

(2010) K. Kojima et al.   MOLECULAR CANCER THERAPEUTICS

Pharmacological reactivation of mutant p53: from protein structure to the cancer patient

(2010) K G Wiman   ONCOGENE

Therapeutic targeting of p53 by small molecules

(2010) Galina Selivanova   SEMINARS IN CANCER BIOLOGY

The Tumor Suppressor p53: From Structures to Drug Discovery

(2010) A. C. Joerger et al.   Cold Spring Harbor Perspectives in Biology

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13

(2009) D. Reece et al.   BLOOD

Perifosine plus nutlin-3 combination shows a synergistic anti-leukaemic activity

(2009) Rebecca Voltan et al.   BRITISH JOURNAL OF HAEMATOLOGY

MDM2-Dependent Downregulation of p21 and hnRNP K Provides a Switch between Apoptosis and Growth Arrest Induced by Pharmacologically Activated p53

(2009) Martin Enge et al.   CANCER CELL

PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain

(2009) Jeremy M.R. Lambert et al.   CANCER CELL

Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib

(2009) M. G. Ooi et al.   CLINICAL CANCER RESEARCH

MDM2 Antagonist Nutlin-3 Displays Antiproliferative and Proapoptotic Activity in Mantle Cell Lymphoma

(2009) Y. Tabe et al.   CLINICAL CANCER RESEARCH

Exposure of B Cell Chronic Lymphocytic Leukemia (B-CLL) Cells to Nutlin-3 Induces a Characteristic Gene Expression Profile, which Correlates with Nutlin-3-Mediated Cytotoxicity (Supplementry Table)

(2009) G. Zauli et al.   CURRENT CANCER DRUG TARGETS

P53 Family: At the Crossroads in Cancer Therapy

(2009) S. Alsafadi et al.   CURRENT MEDICINAL CHEMISTRY

Restoration of p53 to limit tumor growth

(2009) Wenge Wang et al.   CURRENT OPINION IN ONCOLOGY

Pharmacological activation of the p53 pathway in haematological malignancies

(2009) M. N Saha et al.   JOURNAL OF CLINICAL PATHOLOGY

New targets for the treatment of follicular lymphoma

(2009) Nishant Tageja et al.   Journal of Hematology & Oncology

Update in the management of chronic lymphocytic leukemia

(2009) Kami J Maddocks et al.   Journal of Hematology & Oncology

The expression levels of the pro-apoptotic XAF-1 gene modulate the cytotoxic response to Nutlin-3 in B chronic lymphocytic leukemia

(2009) P Secchiero et al.   LEUKEMIA

The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lymphoma with wild-type or mutated p53

(2009) E Drakos et al.   LEUKEMIA

Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein–Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cells

(2009) B Renouf et al.   LEUKEMIA

Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis

(2009) K Kojima et al.   LEUKEMIA

Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells

(2009) H Hasegawa et al.   LEUKEMIA

Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma

(2009) E Drakos et al.   LEUKEMIA

An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals

(2009) Ramzi M Mohammad et al.   Molecular Cancer

Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy

(2008) Sanjeev Shangary et al.   Annual Review of Pharmacology and Toxicology

p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism

(2008) A. J. Steele et al.   BLOOD

Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5

(2008) B. Z. Carter et al.   BLOOD

Mutated and non-mutated TP53 as targets in the treatment of leukaemia

(2008) H. Nahi et al.   BRITISH JOURNAL OF HAEMATOLOGY

p53: A Guide to Apoptosis

(2008) Erik Meulmeester et al.   CURRENT CANCER DRUG TARGETS

The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML

(2008) K Kojima et al.   LEUKEMIA

MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2

(2008) L Gu et al.   LEUKEMIA

Inhibition of the Akt/survivin pathway synergizes the antileukemia effect of nutlin-3 in acute lymphoblastic leukemia cells

(2008) N. Zhu et al.   MOLECULAR CANCER THERAPEUTICS

Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway

(2008) J. E. Kravchenko et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA